Alfacalcidol-d7

Alfacalcidol-d7

• UNSPSC Description: Alfacalcidol-d7 is the deuterium labeled Alfacalcidol. Alfacalcidol (1-hydroxycholecalciferol) is a vitamin D active metabolites, acts as a non-selective VDR activator medication, and widely be used in the management of osteoporosis[1][2][3][4].
• Target Antigen: Isotope-Labeled Compounds; VD/VDR
• Type: Isotope-Labeled Compounds
• Related Pathways: Others;Vitamin D Related/Nuclear Receptor
• Field of Research: Metabolic Disease
• Solubility: 10 mM in DMSO
• Smiles: C=C1[C@H](C[C@@H](C/C1=C/C=C2[C@]3([C@@](C)([C@H](CC3)[C@@H](CCCC([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])C)CCC/2)[H])O)O
• Molecular Weight: 407.68
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Galeşanu C, et al. [Postmenopausal osteoporosis. Digital Rx radiogrammetry in the diagnosis and follow-up of treatment with alfacalcidol]. Rev Med Chir Soc Med Nat Iasi. 2006 Oct-Dec;110(4):833-41.|[3]Nuijten M, et al. Cost Effectiveness of Paricalcitol versus a Non-Selective Vitamin D Receptor Activator for Secondary Hyperparathyroidism in the UK. Clin Drug Investig. 2010;30(8):545-57.|[4]Shiraishi A, et al. The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int. 1999 Oct;65(4):311-6.|[5]Nagaoka H, et al. Alfacalcidol enhances collagen quality in ovariectomized rat bones. J Orthop Res. 2014 Aug;32(8):1030-6.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported